Catalyst
Slingshot members are tracking this event:
Top line Phase 3 data of Epidiolex for Dravet Syndrome expected 1Q 2016 (first trial)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GWPH | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 14, 2016
Occurred Source:
http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Phase%203%20Pivotal%20Study%20Results%20for%20Epidiolex%20cannabidiol.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Epidiolex, Dravet Syndrome, 1q, Phase 3
